- E-mailRolf.Bjerkvig@uib.no
- Phone+47 55 58 63 52+47 951 18 268
- Visitor AddressJonas Lies vei 91
- Postal AddressPostboks 78045020 Bergen
Rolf Bjerkvig (f. 1953) is Professor for cell biology and has since the ealy 80s worked in experimental cancer biology.
Dr Bjerkvig receives major grants from the Norwegian Research Council, The Norwegian Cancer Society and the European Commission. He is on the editorial board on several international journals and is sitting in several national as well as international funding committees for cancer research in Europe. He has published more than 200 articles in scientific literature and has received a number of research prizes for his work. In 2015, Bjerkvig was awarded the King Olav V Research Prize in Cancer Research.
- 2020. Tumor-penetrating peptide for systemic targeting of Tenascin-C. Scientific Reports.
- 2020. Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects. Neuro-Oncology Advances (NOA).
- 2020. Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology. Acta Neuropathologica. 1-31.
- 2020. Identification of a Blood-Based Protein Biomarker Panel for Lung Cancer Detection. Cancers.
- 2020. AN1-type zinc finger protein 3 (ZFAND3) is a transcriptional regulator that drives Glioblastoma invasion. Nature Communications.
- 2019. Therapeutic implications of altered cholesterol homeostasis mediated by loss of CYP46A1 in human glioblastoma. EMBO Molecular Medicine.
- 2019. Peptide-guided nanoparticles for glioblastoma targeting. Journal of Controlled Release. 109-118.
- 2019. Long Noncoding RNA SChLAP1 Forms a Growth-Promoting Complex with HNRNPL in Human Glioblastoma through Stabilization of ACTN4 and Activation of NF-kappa B Signaling. Clinical Cancer Research. 6868-6881.
- 2019. Improved drug delivery to brain metastases by peptide-mediated permeabilization of the blood-brain barrier. Molecular Cancer Therapeutics. 2171-2181.
- 2019. Effective treatment of metastatic melanoma by combining mapk and pi3k signaling pathway inhibitors. International Journal of Molecular Sciences. 1-19.
More information in national current research information system (CRIStin)
1987: Dr. philos. The Gade Institute of Pathology, University of Bergen
1981: M.Sc. Immunology, University of San Francisco, 1981.